SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Recruiting · NCT05770687 · Observational (researchers observe without assigning treatment) · Lead sponsor: Kiyuk Chang
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
Who can take part
Inclusion criteria
- Acute myocardial infarction who were treated with percutaneous coronary intervention
- Type 2 diabetes mellitus
- Started SGLT2 inhibitors \<1 month before/after PCI
Exclusion criteria
- Type 1 diabetes mellitus
- Insulin / GLP-1 analogue users
- Previous users of SGLT2 inhibitors
- Pregnancy
Where it is running
1 location listed.
- Seoul St. Mary's Hospital - Seoul, South Korea